Online inquiry

IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15733MR)

This product GTTS-WQ15733MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SEMA4D gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001142287.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10507
UniProt ID Q92854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15733MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11873MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ3032MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ8240MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ4378MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ13559MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ4026MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ15660MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ5946MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW